Accumulating evidence from clinical studies of breast cancers has demonstrated that elevated serum levels of YKL-40 correlate with cancer progression and decreased disease-free survival (Johansen et al, 1995; Jensen et al, 2003). Here, CHI3L1 is linked to breast cancer.